Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01886469
Recruitment Status : Completed
First Posted : June 26, 2013
Last Update Posted : October 3, 2014
Sponsor:
Information provided by (Responsible Party):
Ironshore Pharmaceuticals and Development, Inc

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : September 2013
Actual Study Completion Date : September 2013